Event Type
Disclosure
Mandatory
Variant
8-K
Termination of a Material Definitive Agreement. On January 5, 2026, Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc., and ImmuneOnco Bio